{
    "clinical_study": {
        "@rank": "48482", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Paracetamol Tablet", 
                "arm_group_type": "Experimental", 
                "description": "Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water."
            }, 
            {
                "arm_group_label": "Standard Paracetamol Tablet (500 mg)", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard paracetamol tablet (500 mg) administered with 240 mL of water."
            }
        ], 
        "brief_summary": {
            "textblock": "A pharmacokinetic study in healthy volunteers comparing  two formulations of paracetamol\n      fast release in fasted state."
        }, 
        "brief_title": "Pharmacokinetic Study to Compare Two Formulations of Paracetamol", 
        "completion_date": {
            "#text": "April 2010", 
            "@type": "Actual"
        }, 
        "condition": [
            "Fever", 
            "Headache Disorders", 
            "Pain"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Headache Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers aged 18-55yrs willing to give written informed consent for\n             the study\n\n          -  BMI must be within the range 18.5 - 24.9 kg/m^2\n\n          -  Participant with a minimum weight of 50 kg\n\n        Exclusion Criteria:\n\n          -  Participant with current or recurrent disease that could affect the action,\n             absorption or disposition of the study medication or clinical or laboratory\n             assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure)\n\n          -  Participant with known or suspected intolerance or hypersensitivity to the study\n             materials\n\n          -  Participant who are vegetarian\n\n          -  Participant smoking more than five cigarettes a day"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767428", 
            "org_study_id": "A1900832"
        }, 
        "intervention": {
            "arm_group_label": [
                "Experimental Paracetamol Tablet", 
                "Standard Paracetamol Tablet (500 mg)"
            ], 
            "description": "500 mg immediate release paracetamol formulations", 
            "intervention_name": "Paracetamol", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Acetaminophen"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Pharmacokinetic Study to Evaluate the Rate and Extent of Absorption of Paracetamol From Two Formulations in an Indian Population.", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: IEC", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration time curve from zero and extrapolated to infinite time.", 
                "measure": "AUC (0-inf)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose."
            }, 
            {
                "description": "Maximum plasma concentration of paracetamol.", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose."
            }, 
            {
                "description": "Area under the plasma concentration time curve from zero and extrapolated to the time of last quantifiable sample.", 
                "measure": "AUC (0-t)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767428"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Time taken to reach maximum plasma concentration of paracetamol.", 
            "measure": "Tmax", 
            "safety_issue": "No", 
            "time_frame": "Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose."
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}